Vertex Pharmaceuticals | VRTX - Interest Expense On Debt

Stock Price
481.03
Daily Change
4.13 0.87%
Monthly
0.88%
Yearly
-0.13%
Q1 Forecast
462.12

Vertex Pharmaceuticals reported $3.3M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Arrowhead Research USD 22.5M 811K Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Gilead Sciences USD 255M 1000K Dec/2025
Incyte USD 582K 10K Dec/2025
Insmed USD 20.6M 217K Dec/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
J&J USD 18M 290M Sep/2025
Merck USD 412M 85M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
United Therapeutics USD 3M 4.3M Sep/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025